Omnicell (NASDAQ:OMCL) Upgraded to Buy by StockNews.com

StockNews.com upgraded shares of Omnicell (NASDAQ:OMCL) from a hold rating to a buy rating in a research report report published on Wednesday.

Other analysts have also issued research reports about the company. Wells Fargo & Company increased their target price on Omnicell from $26.00 to $30.00 and gave the company an equal weight rating in a report on Friday, August 2nd. Benchmark reissued a buy rating and issued a $38.00 price objective on shares of Omnicell in a research note on Monday, July 15th. JPMorgan Chase & Co. lifted their target price on Omnicell from $26.00 to $37.00 and gave the company a neutral rating in a research note on Friday, August 23rd. Barclays raised shares of Omnicell from an underweight rating to an equal weight rating and increased their price target for the stock from $26.00 to $39.00 in a research report on Friday, August 2nd. Finally, Bank of America boosted their price objective on shares of Omnicell from $34.00 to $44.00 and gave the company a buy rating in a research report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $37.83.

Omnicell Trading Up 0.8 %

Shares of OMCL opened at $43.16 on Wednesday. The business’s 50-day moving average price is $37.42 and its 200 day moving average price is $31.63. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $1.98 billion, a P/E ratio of -93.83, a P/E/G ratio of 47.48 and a beta of 0.83. Omnicell has a 1-year low of $25.12 and a 1-year high of $56.06.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.37. The business had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share. Analysts expect that Omnicell will post 0.64 earnings per share for the current year.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in OMCL. Panagora Asset Management Inc. bought a new position in Omnicell during the fourth quarter valued at about $1,319,000. Vanguard Group Inc. increased its holdings in shares of Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after acquiring an additional 80,312 shares during the last quarter. Mutual of America Capital Management LLC raised its stake in shares of Omnicell by 197.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock valued at $3,642,000 after acquiring an additional 82,774 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after purchasing an additional 228,093 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Omnicell during the first quarter worth approximately $684,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.